PMC:7091888 / 30191-30866
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1174 | 198-208 | Gene | denotes | hACE2/293T | Gene:59272 |
| 1175 | 35-45 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 1176 | 136-146 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 1177 | 315-325 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 1178 | 339-347 | Species | denotes | SARS-CoV | Tax:694009 |
| 1179 | 381-389 | Species | denotes | SARS-CoV | Tax:694009 |
| 1180 | 406-414 | Species | denotes | MERS-CoV | Tax:1335626 |
| 1181 | 301-309 | Disease | denotes | infected | MESH:D007239 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T243 | 50-57 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T244 | 151-158 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T245 | 216-221 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T246 | 277-284 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T247 | 290-295 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T248 | 494-499 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
| T249 | 596-603 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T509 | 35-43 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T510 | 35-39 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T511 | 136-144 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T512 | 136-140 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T513 | 315-323 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T514 | 315-319 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T515 | 339-347 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T516 | 339-343 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T517 | 381-389 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T518 | 381-385 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T510 | 204-208 | http://purl.obolibrary.org/obo/CLO_0050894 | denotes | 293T |
| T511 | 204-208 | http://purl.obolibrary.org/obo/CLO_0051650 | denotes | 293T |
| T512 | 204-208 | http://purl.obolibrary.org/obo/CLO_0052052 | denotes | 293T |
| T513 | 216-221 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T514 | 290-295 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
| T515 | 494-499 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cells |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T168 | 50-57 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T169 | 151-158 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T170 | 277-284 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T171 | 596-603 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T175 | 0-239 | Sentence | denotes | Inhibition of pseudovirus entry by SARS-CoV-2 RBD protein was carried out, as previously described, with some modifications.31 Briefly, SARS-CoV-2 RBD protein at serial dilutions was incubated with hACE2/293T target cells for 1 h at 37 °C. |
| T176 | 240-338 | Sentence | denotes | After removing medium containing the protein, the cells were infected with SARS-CoV-2 pseudovirus. |
| T177 | 339-450 | Sentence | denotes | SARS-CoV RBD and MERS-CoV RBD, as well as SARS-CoV pseudovirus and MERS-CoV pseudovirus, were used as controls. |
| T178 | 451-544 | Sentence | denotes | Fresh medium was added 24 h later, and the cells were lysed and analyzed, as described above. |
| T179 | 545-675 | Sentence | denotes | The 50% inhibitory concentration (IC50) of the RBD protein was calculated using the CalcuSyn computer program, as described above. |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32203189-27750111-19774551 | 124-126 | 27750111 | denotes | 31 |